TREATMENT ACCESS
Advanced treatment access,
organized around clinical capability.
Vialen treatment programs are structured around defined clinical capability, center-specific review requirements and case-level eligibility. Each pathway moves forward only where the relevant clinical requirements and treatment route can be clearly established.
01
Cellular & Gene Therapies
CAR-T and other highly specialized cell-based treatment pathways for selected cases, including blood cancers and selected solid-tumor cellular-therapy programs.
02
Particle & Advanced Radiation
Case-specific evaluation of proton, carbon-ion and other advanced radiation programs, weighed against anatomy, prior treatment and center-specific review criteria.
CASE DEPENDENCIES
Diagnosis
Prior radiation
Anatomy
Current imaging
Treatment history
Center-specific clinical review
03
Complex Oncology
Complex oncology requires capability-specific review. The relevant pathway depends on the clinical problem, prior treatment and specialist capability required.
International review for rare tumors and treatment-resistant cases requiring multidisciplinary evaluation and cross-border access where highly specialized capability exists, not a general cancer-treatment promise.
04
Specialized & Case-Specific Therapies
Uncommon or evolving treatment options, carefully evaluated through qualified clinical centers and specialist programs, developed only where a credible route can be formed.
Vialen does not treat breadth as a catalogue. A pathway is developed only where a credible treatment-specific capability can be identified.
ONCOLOGY FIRST
Vialen opens a treatment area only when the route is real.
Oncology is the first treatment area Vialen has built around verified capabilities, receiving teams and cross-border access routes. Additional specialties are added only when the same standard can be met.
LIVE NOW
Advanced Oncology
CAR-T, complex oncology and advanced radiation routes where case-specific capability can be verified.
NEXT, ONLY WHEN VERIFIED
Additional specialist capabilities
Additional specialist capabilities are added only when a defined clinical-review route and executable access pathway are in place.
CAPABILITY ACROSS SYSTEMS
China is an important part of Vialen’s operating depth, not a default destination. The relevant route depends on the treatment capability the case requires, the receiving team’s current criteria and whether the path can actually be executed.
Not every advanced treatment is appropriate for every case.
Vialen begins with the clinical question, available records and prior treatment history. The relevant treating institution determines suitability, additional testing and whether a treatment route can move forward.